The Guangzhou Saiaojin Cancer Hospital International Alliance serves as the strategic core carrier for the Sino-US Saiaojin Cancer Chain Group, anchoring its focus on the frontier of innovative biomedicine and laying out the development of core technologies and the transformation of clinical achievements. Leveraging the group's four decades of deep expertise in the biopharmaceutical field, including core technological barriers, global industrial resources, and mature cross-regional operational experience, the hospital focuses on major health needs such as cancer treatment. It has built a full-chain core competitiveness in the fields of biopharmaceuticals and cell therapy, encompassing research and development, translation, production, and globalization. It is committed to creating an international cell tumor diagnosis and treatment alliance that combines Chinese original genes with a global perspective.